







an Open Access Journal by MDPI

# Emerging and Re-emerging Animal Viral Diseases and Viral Diseases with Zoonotic Potential

Guest Editors:

Dr. Giulia Franzoni

Dr. Miriam Pedrera

Dr. Pedro J. Sanchez-Cordon

Deadline for manuscript submissions:

closed (30 November 2023)

## **Message from the Guest Editors**

This Special Issue aims to show novel and high impact results in the field of emerging and re-emerging viral diseases that may affect livestock, poultry and wild animals, and that can also cause disease in humans (zoonoses). The current issue will be opened not just to manuscripts focused on vaccine development and new antigen discovery, but also to studies focused on viruses replication and spread, viruses transmission, pathogenic mechanisms, virus—host interactions, immune response induced against virus infections, immune mechanisms involved in protection or any other state-of- the-art study that might contribute to prevent and control these viral diseases in livestock and the transmission from animal to human

We encourage authors to present original results obtained after carrying out "in vivo" experiments that require the use of small animal models (e.g., murine models), as well as natural or intermediate hosts. We will also consider "in vitro" studies. Only high-quality reviews tackling novel issues in the field will be considered













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### **Contact Us**